CD274 and small cell lung carcinoma: These results indicate that treatment with AZD1775 plus anti-PD-L1 antibody significantly increases cytotoxic T cell infiltration and enhances the antitumor effects in a high-MYC-expressing aggressive in vivo subcutaneous model of SCLC.